首页|抑制肺鳞癌靶点HMGCS1促进细胞铁死亡

抑制肺鳞癌靶点HMGCS1促进细胞铁死亡

扫码查看
背景与目的 靶向治疗在肺鳞癌中的效果不理想,而免疫治疗较低的应答率阻碍了其在肺鳞癌中的应用,因此,探索肺鳞癌治疗的新策略十分迫切.铁死亡在抑制肿瘤方面发挥了重要作用,本研究旨在探究靶向3-羟基-3-甲基戊二酰辅酶A合酶1(3-hydroxy-3-methylglutaryl-CoA synthase 1,HMGCS1)对肺鳞癌细胞铁死亡的调控和作用机制,为肺鳞癌治疗提供新的研究思路和方向.方法 通过肿瘤基因组图谱(The Cancer Genome Atlas,TCGA)和临床蛋白质组肿瘤分析联盟(Clinical Proteomic Tumor Analysis Consortium,CPTAC)在线蛋白数据库分析HMGCS1在肺鳞癌中的表达情况;通过Kaplan-Meier Plotter在线生存数据库分析HMGCS1与肺癌生存时间的关系;通过免疫组化验证HMGCS1在肺鳞癌组织的表达水平;在肺鳞癌细胞系SKMES细胞通过小干扰RNA(small interfering RNA,siRNA)干扰HMGCS1表达后,通过CCK8和Transwell检测细胞活性和细胞迁移能力;通过流式细胞术检测干扰HMGCS1后或用HMGCS1抑制剂hymeglusin处理后细胞凋亡水平;通过流式和高内涵共聚焦荧光成像系统分别检测抑制HMGCS1后SKMES细胞中Fe2+、活性氧(reactive oxygen species,ROS)和脂质过氧化水平;通过Western blot检测抑制HMGCS1后铁死亡通路标志蛋白ACSL4、GPX4和SLC7A11表达.结果 HMGCS1 mRNA和蛋白水平在肺鳞癌均显著高表达;siRNA干扰HMGCS1表达抑制了肺鳞癌细胞增殖活性和迁移能力,但对细胞凋亡没有显著影响.干扰HMGCS1后或用HMGCS1抑制剂hymeglusin处理后显著促进了SKMES细胞内Fe2+、ROS和脂质过氧化水平,促进肺鳞癌细胞铁死亡;Western blot检测显示抑制HMGCS1显著促进了ACSL4的表达.结论 抑制肺鳞癌靶点HMGCS1可促进肺癌细胞铁死亡,为肺鳞癌筛选新的治疗靶点提供了研究基础.
Inhibition of Lung Squamous Cancer Target HMGCS1 Promotes Cellular Ferroptosis
Background and objective Targeted therapies are ineffective in lung squamous cancer(LUSC),and the low response rate of immunotherapy hampers its application in LUSC,so it is urgent to explore new strategies for LUSC treat-ment.Ferroptosis plays an important role in tumour suppression.The aim of this study was to investigate the role and mecha-nism of targeting 3-hydroxy-3-methylglutaryl-CoA synthase 1(HMGCS1)in regulating ferroptosis in LUSC cells,in order to provide a new research direction for LUSC therapy.Methods The expression of HMGCS1 in LUSC was analysed by The Cancer Genome Atlas(TCGA)and Clinical Proteomic Tumor Analysis Consortium(CPTAC)online databases;the relation-ship between HMGCS1 and survival time of lung cancer was analysed by the Kaplan-Meier Plotter online survival database;the expression level of HMGCS1 in LUSC tissues was verified by immunohistochemistry.After interfering with HMGCS1 expression by small interfering RNA(siRNA),cell activity and cell migration ability were detected by CCK8 and Transwell as-say;apoptosis was detected by flow cytometry after interfering with HMGCS1 or after treatment with the HMGCS1 inhibitor of hymeglusin;Fe2+,reactive oxygen species(ROS)and lipid peroxidation levels were detected by flow cytometry and high-content confocal fluorescence imaging systems,respectively in SKMES cells after inhibition of HMGCS1;and Western blot was performed to detect the expression of ACSL4,GPX4 and SLC7A11,which are markers of the ferroptosis pathway after in-hibition of HMGCS1.Results HMGCS1 mRNA and protein levels were significantly high in LUSC;siRNA interference with HMGCS1 expression inhibited the proliferative activity and migration ability of LUSC cells,but had no significant effect on apoptosis.Interference with HMGCS1 or treatment with the HMGCS1 inhibitor of hymeglusin significantly promoted intra-cellular Fe2+,ROS and lipid peroxidation levels in SKMES cells,and induced ferroptosis in LUSC cells;Western blot assay showed that inhibition of HMGCS1 significantly promoted the expression of ACSL4.Conclusion Inhibition of HMGCS1,a target of LUSC,promotes ferroptosis in lung cancer cells and provides a research basis for screening new therapeutic targets for LUSC.

Lung neoplasmsHMGCS1FerroptosisHymeglusin

倪银芸、杨瑛、张立

展开 >

610000 成都,四川大学华西医院疾病分子网络前沿科学中心呼吸健康研究所

肺肿瘤 HMGCS1 铁死亡 Hymeglusin

国家自然科学基金项目

82173251

2024

中国肺癌杂志
中国抗癌协会 中国防痨协会 天津医科大学总医院

中国肺癌杂志

CSTPCD北大核心
影响因子:1.397
ISSN:1009-3419
年,卷(期):2024.27(5)